NEW YORK (GenomeWeb News) – Oncodesign today announced an agreement with Eisai to assess the use of Halaven Injection (eribulin) in earlier line treatment of metastatic breast cancer.
Oncodesign will conduct in vivo pharmacology studies and Eisai will perform gene expression profiling analysis using Oncodesign's patient-derived xenograft models to evaluate Eisai's Halaven, a non-taxane microtubule dynamics inhibitor. Oncodesign could receive up to €1.25 million ($1.56 million) in revenue for its contributions and has received €900,000 to date, it said.
Based in Dijon, France, Oncodesign supports drug development firms discovering therapeutic molecules directed against cancer and other diseases.